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Abstract: Heart failure (HF) has several etiologies including myocardial infarction (MI) and left 24 
ventricular remodeling (LVR), but its progression remains difficult to predict in clinical practice. 25 
Systems biology analyses of LVR after MI predict molecular insights of this event such as 26 
modulation of microRNA (miRNA) that could be used as a signature of HF progression. To define 27 
a miRNA signature of LVR after MI, we use 2 systems biology approaches integrating either 28 
proteomic data generated from LV of post-MI rat induced by left coronary artery ligation or 29 
multi-omics data (proteins and non-coding RNAs) generated from plasma of post-MI patients from 30 
the REVE-2 study. The first approach predicts 13 miRNAs and 3 of these miRNAs were validated 31 
to be associated with LVR in vivo: miR-21-5p, miR-23a-3p and miR-222-3p. The second approach 32 
predicts 24 miRNAs among 1310 molecules and 6 of these miRNAs were selected to be associated 33 
with LVR in silico: miR-17-5p, miR-21-5p, miR-26b-5p, miR-222-3p, miR-335-5p and miR-375. We 34 
identified a signature of 7 microRNAs associated with LVR after MI that support the interest of 35 
integrative systems biology analyses to define a miRNA signature of HF progression. 36 
Keywords: biomarkers; miRNAs; heart failure; system biology 37 
 38 
1. Introduction 39 
Heart failure (HF) is a major cause of mortality in occidental countries that is difficult to predict 40 
in clinical practice [1]. HF can be the consequence of left ventricle remodeling (LVR) induced by a 41 
myocardial infarction (MI) [2,3]. LVR is characterized by cardiac hypertrophy and reduction of LV 42 
wall. Although, LVR is an adaptive response early after MI, it is becoming deleterious in a long term 43 
[4]. Deciphering molecular events underlying LVR may offer new opportunities in the identification 44 
of early predictive biomarkers of LVR and HF. Omics approaches including transcriptomics, 45 
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proteomics, and metabolomics have been extensively used to explore these mechanisms but the 46 
amount of complex generated data prevents from their comprehensive analysis.  47 
Recently, systems biology opened new opportunities to understand molecular networks and 48 
identify new targets involved in HF [5,6]. Among those potential targets, microRNAs (miRNAs) are 49 
non-coding RNAs of 19 to 23 nucleotides that regulate gene expression by targeting messenger 50 
RNAs [7]. MiRNAs are involved in many processes like cardiomyocyte hypertrophy, fibroblast to 51 
myofibroblast transformation and cell to cell communication [8–10]. The modulation of expression 52 
of a small set of miRNAs associated with LVR may define a miRNA signature to detect this process. 53 
The present study aims to define a signature of miRNAs associated with LVR after MI to predict HF. 54 
We analyzed two systems biology approaches that we previously developed from post MI rat model 55 
[10-13] and post-MI patients from the REVE-2 study [14]. 56 
2. Results 57 
2.1. Analysis of the protein-miRNA network derived from post-MI rats identified circulating miR-21-5p, 58 
miR-23a-3p and miR-222-3p to be associated with LVR after MI 59 
The proteomic screening in LV of post-MI male rats [11], previously published [12,13], allowed 60 
the identification of 45 proteins modulated by LVR. Using the Qiagen’s Ingenuity Pathway 61 
knowledge base, we built a protein-miRNA interaction network highlighting 13 candidate miRNAs 62 
which were prioritized to identify candidate miRNAs to detect LVR after MI (Figure 1). 63 
 64 
Figure 1. Identification of miR-21-5p, miR-23a-3p and miR-222-3p to detect left ventricular 65 
remodeling (LVR) after myocardial infarction (MI) and to predict heart failure (HF). (A) Design and 66 
(B) experimental selection and validation of the 13 candidate miRNAs predicted from the proteomic 67 
data obtained in LV of post-MI rats by the Ingenuity Pathway knowledge platform. Quantification of 68 
candidate miRNAs in LV and in plasma of post-MI rats at 7 days (Timepoint 0) and at 2 months and 69 
in plasma of REVE-2 patients at baseline (Timepoint 0), 3 month and 12 months after MI was 70 
published elsewhere [10]. ↑ and ↓ indicates respectively a significant increase and decrease of 71 
miRNAs (p < 0.05) detected between sham- and post-MI rats / between patients with no and high 72 
LVR, ↔ indicates no modulation, X indicates a lack of detection. MiRNAs remaining after the 73 
validation process are in bold. 74 
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The 13 candidate miRNAs are predicted to interact with 8 out of the 45 proteins modulated by 75 
LVR [10], testifying that they are involved in LVR after MI. Moreover, 9 out of the 13 candidate 76 
miRNAs have been described as biomarkers of HF: miR-21-3p, miR-21-5p, miR-23a-3p, miR-29b-3p, 77 
miR-122, miR-133a, miR-145-5p, miR-222-3p and miR-320a [10,15-20], confirming their potential as 78 
targets to predict HF (Figure 1A). To prioritize candidate miRNAs with high relation specificity with 79 
LVR, we evaluated in vivo the association of the 13 candidate miRNAs with LVR after MI (Figure 80 
1B). In LV of post-MI rats, we selected 6 candidate miRNAs up-regulated by LVR at 7 days 81 
(miR-23a-3p, miR-222-3p and miR-320a) and at 2 months after MI (miR-21-3p, miR-21-5p, 82 
miR-222-3p and miR-377-5p) [10] and we excluded the 7 candidate miRNAs which were not 83 
detected (miR-122 and miR-210) or not modulated by LVR (miR-29b-3p, miR-133a, miR-145-5p, 84 
miR-338-3p and miR-483-3p). In plasma of post-MI rats, we selected 3 candidate miRNAs 85 
down-regulated by LVR at 7 days and up-regulated by LVR at 2 months (miR-21-5p, miR-23a-3p 86 
and miR-222-3p) [10] and we excluded the 3 candidate miRNAs which were not detected (miR-21-3p 87 
and miR-377-5p) or not measurable (miR-320a). In plasma of post-MI patients from the REVE-2 88 
study, we show that the 3 selected candidate miRNAs: miR-21-5p, miR-23a-3p and miR-222-3p are 89 
down-regulated by LVR at baseline and are up-regulated by LVR after 3 months, especially in men, 90 
validating their potential as circulating biomarkers of adverse LVR after MI to predict HF as 91 
previously published [10].  92 
2.2. Analysis of the REVE-2 network identified miR-21-5p, miR-222-3p, miR-335-5p, miR-26b-5p, miR-375 93 
and miR-17-5p to detect LVR after MI 94 
The REVE-2 molecular data generated by the measurement of 24 variables in the plasma of the 95 
patients from the REVE-2 study (including miR-21-5p, miR-23a-3p and miR-222-3p) and the 96 
EdgeLeap’s knowledge platform EdgeBox were used to build the REVE-2 molecular interaction 97 
network described in detail elsewhere [14]. The REVE-2 network contains 1310 molecules, including 98 
24 miRNAs which were prioritized to identify candidate miRNAs to detect LVR after MI (Figure 2). 99 
Fourteen out of the 24 candidate miRNAs are described to be associated with HF: miR-21-5p, 100 
miR-222-3p, miR-423-5p, miR-26b-5p, miR-23a-3p, miR-744-5p, miR-133a-3p, miR-17-5p, 101 
miR-29c-3p, miR-145-5p, miR-29b-3p, let-7g-5p, miR-143-3p and miR-451a [10,15,17,18,21-24], 102 
confirming they are interesting targets to predict HF (Figure 2A-B). To prioritize candidate miRNAs 103 
with high relation specificity with LVR, we evaluated in silico the association of the 24 candidate 104 
miRNAs with LVR after MI through 2 criteria: active modules and betweeness centrality (Figure 105 
2A). To avoid the selection of miRNAs associated with mechanisms not specific of LVR such as 106 
inflammation [14], we excluded the 15 candidate miRNAs active only at baseline. However, it could 107 
be interesting to analyze the miRNAs only active at baseline as potential biomarker of early LVR. To 108 
avoid the selection of miRNAs less significant in LVR, we excluded 13 miRNAs that were not in the 109 
top 50 molecules with the highest centrality. When combining these 2 criteria, among the 24 110 
candidate miRNAs, only 6 remained: miR-21-5p, miR-222-3p, miR-335-5p, miR-26b-5p, miR-375 and 111 
miR-17-5p (Figure 2B). Interestingly, the 6 remaining candidate miRNAs are predicted to be active 112 
at least at 3 months after MI, when only specific mechanisms of LVR seems to be effective [14]. To 113 
date, only miR-21-5p and miR-222-3p, also identified by the first approach, were validated in vivo to 114 
detect LVR after MI [10], testifying that the signature defined by the 6 last candidate miRNAs may 115 
be used as circulating biomarker of adverse LVR after MI to predict HF.  116 
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Figure 2. Identification of miR-21-5p, miR-222-3p, miR-335-5p, miR-26ba-3p, miR-375 and miR-17-5p 118 
to detect left ventricular remodeling (LVR) after myocardial infarction (MI) and to predict heart 119 
failure (HF). (A) Selection process and (B) priorization analysis of the 24 miRNAs predicted from the 120 
multi-omic data obtained in the 226 patients from the REVE-2 study by the EdgeBox knowledge 121 
platform. √ indicates that miRNA is predicted to be active at the corresponding timepoint: baseline 122 
(0), 1 month, 3 month and 12 months after MI. MiRNAs only active at baseline (grey) and with a 123 
betweenness centrality rank lower than 50 (inside the thick line) were excluded from further 124 
investigation because they are not expected to be highly involved in LVR after MI. * indicates 125 
REVE-2 variables. MiRNAs remaining after the selection process are in bold. 126 
2.3. Gene ontology analysis of the 7 miRNAs targets predicted with a high relation specificity with processes 127 
involved in LVR after MI 128 
An analysis of the 7 miRNAs targets was performed using the ClueGO [25] and CluePedia [26] 129 
applications of Cytoscape (version 3.4.0). The applications used the miRecords database to identify 130 
the experimentally validated targets of each miRNA which were submitted to Gene Ontology 131 
enrichment (Figure 3).  132 
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Figure 3. Functional annotation enrichment analysis of the 7 miRNA’s targets. (A) Targets of 134 
miRNAs were predicted by miRecords database. No targets have been described for miR-335-5p and 135 
miR-26b-5p. (Bb) Biological processes of miRNA’s target genes were predicted by Cytoscape plugin 136 
ClueGO and Cluepedia applications (p < 0.05). 137 
Thirty-one targets were predicted to interact with 5 out of 7 miRNAs (miR-21-5p, miR-222-3p, 138 
miR-23a-3p, miR-375 and miR-17-5p) (Figure 3A). The 2 remaining miRNAs (miR-335-5p and 139 
miR-26b-5p) had no validated target in miRecords. We can observe that the miRNA’s targets are 140 
involved in pathways involved in LVR development such as fibroblast proliferation, regulation of 141 
reactive oxygen species metabolism and intrinsic apoptotic signaling pathways, but also embryonic 142 
heart development as embryonic heart tube development and aorta development (Figure 3B). These 143 
results testify of the involvement of the 7 miRNAs in cardiac development and LVR processes.  144 
3. Discussion and Perspectives 145 
Systems biology approaches have been shown to improve the biomarker discovery in 146 
comparison with traditional omics approaches by allowing the selection of biomarkers with a 147 
biological relevance in the pathology [5,6]. In this study, we described two systems biology analyses 148 
integrating both omics data to identify candidate miRNAs associated with LVR after MI and to 149 
predict HF. As interaction networks rely on the use of public databases, prediction of miRNA 150 
interactions are not always experimentally validated and may give an approximate vision of the 151 
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complex mechanisms underlying LVR [27,28]. To avoid this issue, predicted miRNA interactions 152 
were either experimentally validated or predicted by at least 3 different databases in this study. 153 
Moreover, while most systems biology approaches often integrate a single timepoint, we used 154 
different timepoints to integrate the molecular events underlying LVR progression. Finally, both 155 
approaches include a selection of candidate miRNAs associated with LVR after MI either by 156 
experimental validation in vivo or by in silico priorization before validation in post-MI patients. 157 
The first approach, derived from post-MI rat model, predicted 13 candidate miRNAs and 3 of 158 
these candidate miRNAs were selected to be associated with LVR in vivo both in LV and in plasma of 159 
post-MI rats: miR-21-5p, miR-23a-3p and miR-222-3p. In this first approach, candidate miRNAs 160 
were selected based on the hypothesized behavior of circulating miRNAs as endocrine signal, but 161 
our results show that candidate miRNAs does not have necessarily the same profile in LV and in 162 
plasma, testifying that miRNAs secreted by LV are quantitatively and qualitatively different from 163 
their intracellular profile in LV. Moreover, although circulating miRNA profile in HF rat models 164 
may not reflect human profile [29], we validated the association of miR-21-5p, miR-23a-3p and 165 
miR-222-3p with LVR after MI both in plasma of HF rat model and HF patients, testifying that these 166 
3 selected miRNAs define a conserved miRNA signature of LVR. The second approach predicted 24 167 
candidate miRNAs among 1310 molecules and 6 of these miRNAs were selected to be associated 168 
with LVR in silico: miR-17-5p, miR-21-5p, miR-26b-5p, miR-222-3p, miR-335-5p and miR-375. 169 
Although miR-21-5p and miR-222-3p were validated by the first approach, miR-335-5p, miR-26b-5p, 170 
miR-375 and miR-17-5p remain to be validated. Altogether, these two integrative systems biology 171 
analyses identified a signature of 7 microRNAs associated with LVR after MI and more especially 172 
with mechanisms underlying LVR, such as apoptosis, oxidative stress and fibroblasts proliferation. 173 
MiR-21-5p is one of the most studied miRNAs in cardiovascular diseases. Indeed, it was shown 174 
that the failing heart was able to release miR-21-5p into the circulation [18]. Mir-23a-3p is less 175 
studied. However, a correlation was described between miR-23a and pulmonary function of patients 176 
with idiopathic pulmonary hypertension [30]. MiR-23a was also shown to regulate cardiomyocyte 177 
apoptosis by targeting SOD2 mRNA [31]. MiR-222-3p is known to regulate SOD2 expression in HF 178 
patients [10] and to be involved in the inhibition of myocardial fibrosis by targeting TGFβ [32]. 179 
Recently, we showed that miR-21-5p, miR-23a-3p and miR-222-3p were decreased in the plasma of 180 
patients with high LVR at baseline and increased at one year [10]. MiR-335-5p has not been yet 181 
linked with cardiovascular diseases and it has been described as a potential biomarker of 182 
osteosarcoma in children [33] and of osteoporosis [34]. MiR-375 has been shown to be mainly 183 
expressed in the developing heart and to a lower extent in the adult heart [35] and it is also increased 184 
in the plasma of pregnant women with fetal congenital heart defects [36]. MiR-26b-5p and miR-17-5p 185 
are well known to be involved in the cardiovascular system. MiR-26b-5p has been shown to be 186 
modulated in plasma of patients presenting major cardiovascular events [23]. MiR-17-5p was shown 187 
to be increased in the plasma of patients with hypertrophic cardiomyopathy and diffuse myocardial 188 
fibrosis [24]. These results testify that miR-21-5p, miR-23a-3p, miR-222-3p, miR-320a, miR-335-5p, 189 
miR-26b-5p, miR-375 and miR-17-5p may be interesting targets to predict HF. 190 
In conclusion, we highlighted the interest of integrative systems biology analyses to define a 191 
miRNA signature of LVR to predict HF. However, even though the building of molecular networks 192 
relies on experimental data, we showed that miRNA signature still need to be experimentally 193 
validated to be relevant in vivo. 194 
Our study has some limitations: further experiments should be done in order to understand 195 
why there is no correlation for some miRNAs between the intracellular (LV) and extracellular 196 
(plasma) miRNA profiles. It would be important to determine the cellular origin (fibroblasts, 197 
cardiomyocytes, endothelial cells,..) of miRNAs and the characterization of their transporters from 198 
the intracellular to extracellular medium. 199 
4. Methods 200 
4.1. Experimental model of HF in rats 201 
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All animal experiments were performed according to the Guide for the Care and Use of 202 
Laboratory Animals published by the US National Institutes of Health (NIH publication 203 
NO1-OD-4-2-139, revised in 2011). Experimental protocols were performed under the supervision of 204 
a person authorized to perform experiments on live animals (F. Pinet: 59-350126 and E. 205 
Dubois-Deruy: 59-350253). Approval was granted by the institutional ethics review board (CEEA 206 
Nord Pas-de-Calais N°242011, January 2012). MI was induced as previously described [10, 11] by 207 
permanent left anterior descending coronary artery ligation in 10 weeks old Wistar male rats. 208 
Hemodynamic and echocardiographic measurements were performed to detect LVR, at 7 days (n=8 209 
in sham- and MI) and 2 months (n=8 in sham- and MI) after surgery, followed by non-infarcted area 210 
of LV sampling and plasma sampling. 211 
4.2. The REVE-2 study 212 
The REVE-2 study is a prospective multicenter study to analyze the association between 213 
circulating biomarkers and LVR and has been previously detailed [3]. Briefly, REVE-2 study 214 
included 226 patients with a first anterior wall Q-wave MI between February 2006 and September 215 
2008. The research protocol was approved by the Ethics Committee of the Centre Hospitalier et 216 
Universitaire de Lille, and each patient provided written informed consent. Serial echocardiographic 217 
studies were performed at hospital discharge (baseline), 3 months and one year after MI and were 218 
used to assess LVR. LVR was defined as a >20% increase in end diastolic volume from baseline to 1 219 
year. Serial blood samples were taken at 4 timepoint: baseline, 1 month, 3 months and 12 months. 220 
Twenty-four molecular variables were measured in the REVE-2 plasma at 1 to 4 timepoints. 221 
4.3. Quantification of candidate miRNAs 222 
RNAs were extracted from non-infarcted area of LV of rats and from plasma of rats and REVE-2 223 
patients as described elsewhere [10]. Candidate miRNAs were quantified and normalized with 224 
miR-423-3p in LV and with Caenorhabditis elegans Cel-39 in plasma as decribed elsewhere [10]. 225 
4.4. Functional analysis of miRNAs targets 226 
MiRNA target prediction was performed using the ClueGO (version 2.5.2 227 
http://apps.cytoscape.org/apps/cluego) [25] and CluePedia (version 1.5.2 228 
http://apps.cytoscape.org/apps/cluepedia) applications [26] of Cytoscape software (version 3.4.0 229 
http://www.cytoscape.org/). Only validated miRNAs targets from the miRecords database were 230 
selected. A Gene Ontology (GO) enrichment analysis for Biological Processes was performed for all 231 
the miRNAs targets using the ClueGO application of Cytoscape software. P-value was set at 0.05, 232 
and corrected for multiple testing using Benjamini-Hochberg adjustment. 233 
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